Skip to main content
. Author manuscript; available in PMC: 2017 Mar 14.
Published in final edited form as: Neuroscience. 2016 Dec 5;343:77–84. doi: 10.1016/j.neuroscience.2016.11.037

Fig. 4.

Fig. 4

NLRP3 inflammasome inhibitor Ac-YVAD-CMK prevents LPS-induced changes in IL-1β, TNFα, IL-18, TNFα, and IL-10. (A–E) ELISA was used to determine the levels of IL-1β and TNFα in serum (A, B) and IL-1β, IL-18, and TNFα in hippocampus (C–E) on day 3 after LPS injection. IL-1β, IL-18, and TNFα levels were significantly elevated in the LPS group, but not in LPS mice pretreated with Ac-YVAD-CMK (n = 6 mice/group, **p < 0.01 vs. control and YVAD groups, ##p < 0.01 vs. LPS group). (F) ELISA showed that the level of IL-10 in hippocampus on day 3 after LPS injection was significantly decreased in the LPS group, but reversed in the LPS mice pretreated with Ac-YVAD-CMK (n = 6 mice/group, **p < 0.01 vs. control and YVAD groups, ##p < 0.01 vs. LPS group). Data are presented as mean ± SD.